Overview
Balance Sheet
Cash Flow
Growth Analysis
2024
2023
2022
2020
2019
Profitability Metrics
Gross Margin
87.68%
Operating Margin
107.39%
Net Margin
65.15%
Efficiency Metrics
Revenue per Expense Ratio
45,551,154.0
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
107.21%
Income Tax Rate
0.00%
EPS
0.5900000000
Balance Sheet Analysis
Current Ratio
84.18
Cash Ratio
84.35
Working Capital
$51.52M
Debt to Equity
0.63
Debt to Assets
38.39%
Equity Ratio
61.22%
Cash Flow Analysis
Operating Cash Flow Ratio
77.24%
Free Cash Flow Ratio
77.24%
CapEx to Revenue
0.00%
Dividends Paid
$26.82M
Stock Buybacks
$5.54M
Total Shareholder Returns
$32.36M
Cash Position Change
-3,896,133,200.0%
Key Takeaways (2024 FY)
Revenue declined by 5.1049098538232%, indicating potential market challenges
Maintained positive net income growth despite revenue changes
Increased R&D investment by 100.00%
Detailed Growth Metrics
Core Performance
Revenue
-5.10%
Net Income
1,551.39%
EPS
1,648.56%
Operating Income
2,492.57%
Operational Efficiency
R&D Expenses
100.00%
SG&A Expenses
-6.60%
Operating Cash Flow
-67.60%
Free Cash Flow
-67.60%
Balance Sheet Health
Assets
-0.40%
Debt
405,419.67%
Book Value per Share
5.99%
Inventory
0.00%
Shareholder Returns
Dividends per Share
-11.39%
Shares Outstanding
-6.32%
Long Term Trends
3Y Revenue/Share
-5.98%
5Y Revenue/Share
-12.66%
3Y Dividend/Share
-28.05%
5Y Dividend/Share
-15.37%